



Glaxo Group Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS

T +44 2080 475 000
www.gsk.com

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year 2018, holding of:			
a) Shares	6,09,70,500	35.99	35.99
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	6,09,70,500	35.99	35.99

Registered in England and Wales
No. 305979

Registered Office
980 Great West Road, Brentford
Middlesex, TW8 9GS

Name of the Target Company:

Bardhaman

P. J. Mearns

Signature of the Authorised Signatory

Date: 1st April, 2019

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



**Burroughs Wellcome
International Limited**
980 Great West Road
Brentford
Middlesex
TW8 9GS
Tel. +44 (0)20 8047 5000
www.gsk.com

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding


1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Burroughs Wellcome International Limited		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year 2018, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	67,20,000 - - - -	3.97 - - - -	3.97 - - - -
Total	67,20,000	3.97	3.97

Part-B**

Name of the Target Company:

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
Burroughs Wellcome International Limited	Promoter	





Authorised Signatory
For and on behalf of
Glaxo Group Limited
Corporate Director

Signature of the Authorised Signatory

Place: England

Date: 1st April, 2019

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



Eskaylab Limited
 980 Great West Road
 Brentford
 Middlesex
 TW8 9GS
 Tel. +44 (0)20 8047 5000
www.gsk.com

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding


1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Eskaylab Limited		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year 2018, holding of:			
a) Shares	1,17,60,000	6.94	6.94
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	1,17,60,000	6.94	6.94

Part-B**

Name of the Target Company:

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
Eskaylab Limited	Promoter	





Authorised Signatory
For and on behalf of
Glaxo Group Limited
Corporate Director

Signature of the Authorised Signatory

Place: England

Date: 1st April, 2019

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
or			
b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year 2018, holding of:			
a) Shares	4,76,04,024	28.10	28.10
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	4,76,04,024	28.10	28.10

Part-B**

Name of the Target Company:

Name(s) of the person and	Whether the person belongs to	PAN of the person and PACs
Persons Acting in Concert	Promoter/Promoter group	
(PAC) with the person		
GlaxoSmithKline Pte Ltd	Promoter	



Signature of the Authorised Signatory

Debjit Rudra

Place: Director
Singapore

Date: 1st April, 2019

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.